Lanthanum carbonate: Time to abandon prejudices?

Lanthanum carbonate

Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy.

Calciphylaxis is a rare and debilitating vasculopathy predominantly seen in patients with renal failure. The proposed mechanism of injury is active vascular calcification with associated elevated parathyroid hormone, hypercalcemia, or hyperphosphatemia. With improved pharmacologic agents including non-calcium containing phosphate binders, vitamin D analogues, calcimimetics, and bisphosphonates,...

Encephalopathy caused by lanthanum carbonate

Lanthanum carbonate is a nonaluminum, noncalcium phosphate-binding agent, which is widely used in patients with end-stage chronic kidney disease. Until now, no significant side-effects have been described for the clinical use of lanthanum carbonate, and there are no available clinical data regarding its tissue stores. Here we report the case of a 59-year-old patient who was admitted with confus...

Time to abandon nonionic contrast.

E very year, over 1 0 million Intravascular contrast examinations are performed In the United States. A typical dose of 200 mL of high-osmolality Ionic radiographic contrast costs approximately $8 (e.g. , diatrizoate, iothalmate, and others). In comparIson , low-osmolality nonionic contrast costs up to $ 1 70 for equivalent volumes (e.g. , iopamldol. iohexol. and others). If nonlonic contrast w...

Lanthanum carbonate: safety data after 10 years

Despite 10 years of post-marketing safety monitoring of the phosphate binder lanthanum carbonate, concerns about aluminium-like accumulation and toxicity persist. Here, we present a concise overview of the safety profile of lanthanum carbonate and interim results from a 5-year observational database study (SPD405-404; ClinicalTrials.gov identifier: NCT00567723). The pharmacokinetic paradigms of...